| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T292 |
0-11 |
Sentence |
denotes |
Favipiravir |
| T293 |
12-69 |
Sentence |
denotes |
There are 2 published studies on favipiravir in COVID-19. |
| T294 |
70-310 |
Sentence |
denotes |
The first is an open-label RCT for favipiravir vs arbidol conducted in Wuhan, China by Chen et al.92 This study reported digestive tract reactions, including nausea, “anti-acid,” or flatulence in 13.79% (16 of 116) of the favipiravir group. |
| T295 |
311-404 |
Sentence |
denotes |
Hepatotoxicity characterized by any elevation in AST or ALT was reported in 7.76% (9 of 116). |
| T296 |
405-670 |
Sentence |
denotes |
The second is an open-label control study of favipiravir or lopinavir/ritonavir, both used in conjunction with interferon alfa, for COVID-19 by Cai et al,93 which reported diarrhea in 5.7% (2 of 35) and liver injury in 2.9% (1 of 35) (Supplementary Tables 2 and 3). |
